Both of these stocks have strong growth potential.
News & Analysis: AbbVie
These stocks offer high dividend returns without excessive risk.
Interest rates may be at rock-bottom levels, but that doesn't mean income investors can't step into some nice payouts.
These drugmakers' businesses shouldn't be significantly impacted by an economic downturn.
The drug, which AbbVie gained in its acquisition of Allergan, was supposed to be a growth driver for the company.
These three companies can let you take the buy-and-hold philosophy to the extreme.
With the Allergan acquisition freshly closed and revenues from Humira falling, AbbVie needs to get its new products up and running rapidly.
AbbVie scores in the courtroom, in the clinic, and in a collaboration deal.
That's the finding of a clinical trial of ABBV-3373, a new type of antibody-drug conjugate.
The partners will develop and hopefully commercialize up to seven new cancer drugs.